Arbutus Biopharma Corp (ABUS) Cena delnic in novice

Domača stranABUS • NASDAQ

Arbutus Biopharma Corp

4,26 $

16. mar., 08:20:34 GMT -4 · USD · NASDAQ · Izjava

DelnicaVrednostni papir, ki kotira v ZDASedež podjetja: ZDA

Prejšnji trg. dan.

4,26 $

Letni razpon

2,71 $ - 5,10 $

Tržna kapitalizacija

819,30 mio. USD

Povprečni obseg

2,67 mio.

Razm. P/E

Dividendna donosnost

Primarna borza

NASDAQ

Borzne novice

Yahoo Finance

pred 17 minutami

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.

Stock Titan

pred 39 minutami

Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025

The S&P 500's 3 Best-Performing Stocks so far in 2026

Morgan Stanley's Mike Wilson: S&P 500 could trade toward 6,300 by early April

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

.INX

0,00 %

Vizitka

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

Generalni direktor

William H. Collier

Datum ustanovitve

2007

Sedež organizacije

Warminster Township, Pensilvanija
Združene države Amerike

Spletno mesto

arbutusbio.com

Zaposleni